The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Adult Subjects with NTRK Fusion-Positive Tumors.

Alexander E.  Drilon

Honoraria - Exelixis; Genentech/Roche; Ignyta

Consulting or Advisory Role - AstraZeneca; Exelixis; Genentech/Roche

Speakers' Bureau - Ignyta

Research Funding - Foundation Medicine

Travel, Accommodations, Expenses - AstraZeneca; Exelixis; Genentech/Roche; Ignyta

David S.  Hong

Research Funding - Loxo (Inst)

Travel, Accommodations, Expenses - Loxo

Scott  Cruickshank

Consulting or Advisory Role - Loxo

Maegan  Deegan

Employment - Loxo

Stock and Other Ownership Interests  - Loxo

Nora  Ku

Consulting or Advisory Role - Loxo

David Michael  Hyman

No Relationships to Disclose